#USA #Robbins Geller #San Diego #Lawsuit #ADMA Biologics

ADMA Biologics Investors Gear Up for Class Action

ADMA Biologics, Inc., a biopharmaceutical firm specializing in plasma-derived products, is facing serious scrutiny as investors look to initiate a class action lawsuit. Investors who purchased shares between August 9, 2024, and March 25, 2026, are invited to lead the charge, with claims anchored in substantial financial losses.

The deadline for potential lead plaintiffs is set for August 10, 2026. Investors alleging losses have the opportunity to step forward in a case that alleges violations of the Securities Exchange Act of 1934. The class action, titled Mazzarino v. ADMA Biologics, Inc., has drawn attention due to its serious allegations.

Allegations of Misconduct

The crux of the lawsuit lies in allegations that ADMA Biologics and its upper management made misleading statements and failed to disclose critical information during the period in question. Key accusations include:

• - Engaging in undisclosed related party transactions.
• - Practicing channel stuffing, creating the illusion of revenue.
• - Lacking adequate internal controls within the organization.

These claims became more pronounced following a report released by Culper Research on March 24, 2026. Their investigation suggested that reported growth figures were artificially inflated through channel stuffing and undisclosed distributor relationships. In fact, if ADMA Biologics had maintained stable payment terms, the firm would have reported a revenue decrease instead of growth. This revelation led to a significant drop in stock value, further raising eyebrows among investors.

Stock Price Impact

The market reacted sharply to the Culper report. On March 25, the company's stock plummeted over 16% when the findings were made public. Soon after, ADMA attempted to quell the situation by issuing a press release that dismissed the report as speculative and based on unreliable sources. However, investor confidence waned further, culminating in an additional 13% decrease in share value following a downgrade by Cantor Fitzgerald.

How to Join the Class Action

Under the Private Securities Litigation Reform Act of 1995, any individual who purchased ADMA’s securities during the described period is eligible to seek appointment as lead plaintiff. This role is vital, as the lead plaintiff will guide the lawsuit on behalf of the entire class of affected investors. It’s worth noting that being a lead plaintiff is not a requirement to partake in any potential settlements or recoveries.

Interested investors are encouraged to provide their details through legal channels set up by Robbins Geller Rudman & Dowd LLP, the firm spearheading this lawsuit. Those wishing to file or simply seeking information can visit the firm’s dedicated online resource for this case.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is a prominent law firm renowned for defending investors in securities fraud cases. The firm boasts a remarkable track record, having recovered over $916 million for investors in 2025 alone. Their commitment and expertise reinforce their reputation as a leading firm in the realm of class action lawsuits.

As this situation develops, the coming months promise to be eventful for both ADMA Biologics and its investors. For those impacted, the upcoming class action offers a crucial opportunity to seek justice and potential recovery from substantial losses incurred during this turbulent period.